RGEN — Repligen Corporation

Summary of RGEN Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $194 million, a 15% increase year-over-year, with 11% organic growth.
• Gross Profit: $108 million, resulting in a gross margin of 55.5%, up 180 basis points from the previous year.
• Adjusted Operating Income: $30 million, reflecting a 28% year-over-year increase.
• Adjusted Operating Margin: 15.4%, up 160 basis points year-over-year.
• Adjusted EBITDA: $40 million, representing a margin of just under 21%.
• Adjusted Net Income: $27 million, a 22% increase year-over-year.
• Adjusted EPS: $0.48, up from $0.39 in Q1 2025.
• Cash Position: $785 million in cash and marketable securities, up $17 million sequentially.

2. Strategic Updates and Business Highlights:

• Growth Drivers: Strong performance across all customer segments, particularly in Analytics (50%+ growth) and Services (30%+ growth). Capital equipment demand also saw a notable increase.
• Divestiture: Completed the sale of the low-margin Polymem business, which generated $7 million in revenue in 2025, improving overall margins.
• Transformation Office: Launched to optimize manufacturing, improve product line profitability, and enhance IT and AI capabilities, aiming for at least 1% annualized margin benefit by the end of 2027.
• China Partnership: Established an OEM partnership to enhance local manufacturing capabilities, expected to start contributing in 2027.

3. Forward Guidance and Outlook:

• Revenue Guidance: Reiterated full-year revenue guidance of $803 million to $833 million, reflecting 9% to 13% growth.
• Organic Growth Expectations: Maintained guidance for 9% to 13% organic growth.
• Adjusted EPS Guidance: Increased to $1.97 to $2.05, up $0.26 to $0.34 from 2025.
• Margin Expansion: Anticipated gross margin expansion of 110 to 160 basis points for the year.

4. Bad News, Challenges, or Points of Concern:

• Gene Therapy Headwinds: New modalities negatively impacted growth, particularly in gene therapy, although cell therapy showed healthy growth.
• ATF Growth Moderation: Expectations for ATF growth were moderated due to customer-specific timing dynamics, with potential impacts on the second half of the year.
• Emerging Biotech Demand: While there was a 20%+ growth in emerging biotech, demand remains below historical levels, indicating potential volatility.
• Customer Decision-Making Delays: Ongoing delays in customer decision-making processes could affect order fulfillment and revenue recognition.

5. Notable Q&A Insights:

• Order Environment: March saw a significant pickup in orders, attributed to improved customer decision-making and budget releases, with a strong order funnel indicating positive momentum.
• Emerging Biotech Recovery: The company expressed optimism about the biotech funding recovery, which could lead to stronger demand in the back half of the year.
• China Market Dynamics: Most growth in China is driven by local demand rather than multinational expansion, with a strong pipeline of opportunities anticipated.
• Transformation Office Impact: Expected to provide structured improvements in margin expansion, with benefits anticipated to start becoming visible by the end of 2027.

Overall, RGEN reported a strong start to 2026, with solid financial performance and strategic initiatives aimed at sustaining growth and improving margins, despite some challenges in specific segments and external market conditions.